feedback

Course Director

Roy F. Chemaly, MD, MPH, FIDSA, FACP
Roy F. Chemaly, MD, MPH, FIDSA, FACP

The University of Texas MD Anderson Cancer Center
Houston, Texas

Faculty

Genovefa Papanicolaou
Genovefa Papanicolaou, MD

Memorial Sloan Kettering Cancer Center
Weill Cornell Medicine, Medical College
New York, New York

Accredited by

The Medical College of Wisconsin

Activity Details

Credit Types:CME
Credit Amount:1.0 Credits
Release Date:2019-Mar-26
Expiration Date:2020-Mar-25
Estimated Time for Completion:60 minutes
Registration Required:No
Cost:Free of charge

Activity Description and Educational Objectives

Effective antiviral prophylaxis and therapy for opportunistic human cytomegalovirus (CMV) infection in transplant recipients and other immunocompromised hosts has long relied mainly on ganciclovir and its oral prodrug valganciclovir, with foscarnet and cidofovir in secondary roles. Use of these viral DNA polymerase inhibitors has improved clinical outcomes, particularly when used as prophylaxis or preventive therapy, but their use is associated with well-known limitations of toxicity as well as cross-resistance due to the same antiviral drug target. However, after many years of few tangible advances, we are now experiencing an exciting period characterized by novel antiviral agents for CMV. In this activity, based on a recent live symposium held at the 2019 TCT Meetings in Houston, Texas, experts discuss managing CMV in hematopoietic cell transplant (HCT) recipients in a new era of antiviral therapy. Utilizing interactive clinical case scenarios, the expert faculty outlines best practices to prevent CMV infection in patients undergoing HCT and then examine the role of novel antiviral therapies in resistant/refractory CMV.

Upon completion of this activity, participants should be better able to:
  • Identify unmet needs associated with the management of CMV infection in HCT recipients
  • Describe the efficacy and safety of novel strategies to prevent and treat CMV infection in the HCT setting
  • Integrate expert recommendations and recent evidence into the therapeutic decision-making process to prevent and treat CMV infection after HCT

Target Audience

This activity has been designed to meet the educational needs of hematologist-oncologists, oncologists, BMT specialists, BMT nurse specialists, and other clinicians involved in the care of patients undergoing HCT.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: March 26, 2019 - March 25, 2020
Time to Complete: 60 minutes

Faculty and Disclosure / Conflict of Interest Policy

In accordance with ACCME requirements, The Medical College of Wisconsin has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.

Chair & Presenter

Roy F. Chemaly, MD, MPH, FIDSA, FACP
Professor of Medicine
Director, Infection Control Section
Director, Clinical Virology Research
Department of Infectious Disease, Infection Control and Employee Health
The University of Texas MD Anderson Cancer Center
Houston, Texas

Roy F. Chemaly, MD, MPH, FIDSA, FACP, has a financial interest/relationship or affiliation in the form of:
Consultant for Astellas Pharma US, Inc.; Chimerix; Merck & Co., Inc.; Oxford Immunotec; and Shire.
Grant/Research Support from Chimerix; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Oxford Immunotec; and Shire.
Other financial or Material Support from Astellas Pharma US, Inc.; Chimerix; Merck & Co., Inc.; Oxford Immunotec; and Shire as a speaker.

Co-Chair & Presenter

Genovefa Papanicolaou, MD
Member, Director of Clinical Trials, Infectious Disease Service
Memorial Sloan Kettering Cancer Center
Professor of Medicine, Weill Cornell Medicine, Medical College
New York, New York

Genovefa Papanicolaou, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for Astellas Pharma US, Inc.; Chimerix; Clinigen; and Merck & Co., Inc.
Grant/Research Support from Astellas Pharma US, Inc.; Chimerix; Merck & Co., Inc.; and Shire.

The Medical College of Wisconsin (MCW) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by MCW for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

Providership, Credit, and Support

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The Medical College of Wisconsin and PVI, PeerView Institute for Medical Education. The Medical College of Wisconsin is accredited by the ACCME to provide continuing medical education for physicians.

The Medical College of Wisconsin designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Hours of Participation for Allied Health Care Professionals:

The Medical College of Wisconsin designates this activity for up to 1.0 hours of participation for continuing education for allied health professionals.

Providership


This CME activity is jointly provided by The Medical College of Wisconsin and PVI, PeerView Institute for Medical Education.

Support

This activity is supported by independent medical educational grants from Merck & Co., Inc. and Shire.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

About This CME Activity

PVI, PeerView Institute for Medical Education, and The Medical College of Wisconsin are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and The Medical College of Wisconsin.

Copyright © 2000-2019, PeerView

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.